Featured Research

from universities, journals, and other organizations

New method for generating human stem cells is remarkably efficient

Date:
September 30, 2010
Source:
Cell Press
Summary:
The ability to efficiently generate patient-specific stem cells from differentiated cells and then reliably direct them to form specialized cells (like neurons or muscle) has tremendous therapeutic potential for replacing diseased or damaged tissues. However, despite some successes, there have been significant limitations associated with existing methods used to generate human induced pluripotent stem cells.

The ability to efficiently generate patient-specific stem cells from differentiated cells and then reliably direct them to form specialized cells (like neurons or muscle) has tremendous therapeutic potential for replacing diseased or damaged tissues. However, despite some successes, there have been significant limitations associated with existing methods used to generate human induced pluripotent stem cells (iPSCs).

Now, a study published by Cell Press on September 30th in the journal Cell Stem Cell presents a novel strategy for creating iPSCs that exhibits some significant advantages when compared with current iPSC technologies. The new method does not require risky genetic modification and holds great promise for making the reprogramming process more therapeutically relevant.

"Clinical application of iPSCs is currently hampered by low efficiency of iPSC generation and protocols that permanently alter the genome to effect cellular reprogramming," explains senior study author, Dr. Derrick J. Rossi from Harvard Medical School. "Perhaps even more importantly, safe and effective means of directing the fate of patient-specific iPS cells towards clinically useful cell types are lacking."

In the current study, Dr. Rossi and colleagues did not take the standard approach to permanently alter the genome to achieve expression of protein factors known to reprogram adult cells into iPSCs. Instead, they developed synthetic modified messenger RNA molecules (which they termed "modified RNAs") that encoded the appropriate proteins but did not integrate into the cell's DNA.

Repeated administration of the modified RNAs resulted in robust expression of the reprogramming proteins in mature skin cells that were then converted to iPSCs with startling efficiency. "We weren't really expecting the modified RNAs to work so effectively, but the reprogramming efficiencies we observed with our approach were very high," says Dr. Rossi.

Importantly, the modified RNA method was also used to successfully to control the fate of the iPSCs. "Creation of iPSCs is the critical first step towards patient-specific therapies, but to truly realize the promise of iPS cell technology for regenerative medicine or disease modeling, we must harness the potential of iPS cells to generate clinically useful cell types," notes Dr. Rossi. RNA-induced iPSCs with an RNA associated with muscle cell development caused the cells to differentiate into muscle cells -- again simply, efficiently and without the immediate risk of inducing genetic mutations.

These findings demonstrate that the novel RNA-induced iPSC technology offers significant advantages over existing methodologies. "Our technology represents a safe, efficient strategy for somatic cell reprogramming and directing cell fate that has wide ranging applicability for basic research, disease modeling and regenerative medicine," concludes Dr. Rossi. "We believe that our approach has the potential to become a major and perhaps even central enabling technology for cell-based therapies."


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. Luigi Warren, Philip D. Manos, Tim Ahfeldt, Yuin-Han Loh, Hu Li, Frank Lau, Wataru Ebina, Pankaj K. Mandal, Zachary D. Smith, Alexander Meissner, George Q. Daley, Andrew S. Brack, James J. Collins, Chad Cowan, Thorsten M. Schlaeger, and Derrick J. Rossi. Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA. Cell Stem Cell, 2010 DOI: 10.1016/j.stem.2010.08.012

Cite This Page:

Cell Press. "New method for generating human stem cells is remarkably efficient." ScienceDaily. ScienceDaily, 30 September 2010. <www.sciencedaily.com/releases/2010/09/100930142711.htm>.
Cell Press. (2010, September 30). New method for generating human stem cells is remarkably efficient. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2010/09/100930142711.htm
Cell Press. "New method for generating human stem cells is remarkably efficient." ScienceDaily. www.sciencedaily.com/releases/2010/09/100930142711.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins